{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+Age-Related+Macular+Degeneration&page=4",
    "query": {
      "condition": "Neovascular (Wet) Age-Related Macular Degeneration",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+Age-Related+Macular+Degeneration&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+Age-Related+Macular+Degeneration&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T02:36:49.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02461771",
      "title": "Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-01-28",
      "completion_date": "2016-03-08",
      "has_results": true,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Portsmouth",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02461771"
    },
    {
      "nct_id": "NCT05903794",
      "title": "A Study of EXG102-031 in Patients With wAMD (Everest)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular (Wet) Age-related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "EXG102-031",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Exegenesis Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-07-24",
      "completion_date": "2026-02-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 2,
      "location_summary": "Reno, Nevada • Erie, Pennsylvania",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05903794"
    },
    {
      "nct_id": "NCT05891548",
      "title": "Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "CLS-AX",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearside Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-05-31",
      "completion_date": "2024-08-20",
      "has_results": false,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891548"
    },
    {
      "nct_id": "NCT00090623",
      "title": "A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "rhuFab V2 (ranibizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2004-08",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090623"
    },
    {
      "nct_id": "NCT00893724",
      "title": "Supplemental Adjuvants for Intracellular Nutrition and Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Neutral pills with no medicinal effect",
          "type": "DRUG"
        },
        {
          "name": "Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Mid-Atlantic Retina Consultations, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2009-06",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-07-20",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00893724"
    },
    {
      "nct_id": "NCT03345082",
      "title": "A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OPT-302",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sham intravitreal injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Opthea Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 366,
      "start_date": "2017-11-06",
      "completion_date": "2019-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 55,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345082"
    },
    {
      "nct_id": "NCT03362190",
      "title": "ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Avacincaptad Pegol",
          "type": "DRUG"
        },
        {
          "name": "Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2017-10-11",
      "completion_date": "2018-10-18",
      "has_results": true,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03362190"
    },
    {
      "nct_id": "NCT04126317",
      "title": "Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular (Wet) Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "aflibercept",
          "type": "DRUG"
        },
        {
          "name": "High-dose aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2019-11-04",
      "completion_date": "2021-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126317"
    },
    {
      "nct_id": "NCT03066258",
      "title": "Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RGX-314",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 42,
      "start_date": "2017-03-29",
      "completion_date": "2021-06-17",
      "has_results": true,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 8,
      "location_summary": "Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03066258"
    },
    {
      "nct_id": "NCT04635800",
      "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Edema",
        "Diabetic Macular Edema",
        "Neovascular Age-related Macular Degeneration",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "MHU650",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-12-10",
      "completion_date": "2022-05-24",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-10-13T02:36:49.164Z",
      "location_count": 5,
      "location_summary": "Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04635800"
    }
  ]
}